3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
7
Genitourinary
2
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Renal Cell
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasm Metastasis
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Clear-cell metastatic renal cell carcinoma
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Interventions
pembrolizumab
31
Nivolumab
12
Cyclophosphamide
10
fludarabine
9
aldesleukin
8
atezolizumab
7
durvalumab
6
Magnetic Resonance Spectroscopy
6
Trastuzumab
5
Specimen Handling
5
Paclitaxel
5
Ipilimumab
5
Docetaxel
5
Biopsy
5
fludarabine phosphate
4
Radiotherapy
4
Interleukin-2
4
Gene Expression Profiling
4
Carboplatin
4
tisotumab vedotin
3
cemiplimab
3
aflibercept
3
Polymerase Chain Reaction
3
Immunoglobulin G
3
Early Intervention, Educational
3
Cisplatin
3
Bevacizumab
3
tremelimumab
2
tislelizumab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
lenvatinib
×
Genitourinary
×
Clear all
NCT04977453
2026-05-15
Keynote B59
GI Innovation, Inc.
Phase 1/2
Recruiting
317 enrolled
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled